CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to understand cancer development by using TALEN technology to create specific chromosomal deletions in primary human cells. By studying these engineered cells, researchers will investigate the impact of genetic alterations on cancer progression and identify potential therapeutic targets.
Somatically acquired loss-of-heterozygosity (LOH) is extremely common in cancer; deletions of recessive cancer genes, miRNAs, and regulatory elements, can confer selective growth advantage, whereas deletions over fragile sites are thought to reflect an increased local rate of DNA breakage.
However, most LOHs in cancer genomes remain unexplained.
Here we plan to combine a TALEN technology and the experimental models of cell transformation derived from primary human cells to delete specific chromo…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
